Welcome to our dedicated page for NeOnc Technologies Holdings news (Ticker: NTHI), a resource for investors and traders seeking the latest updates and insights on NeOnc Technologies Holdings stock.
NeOnc Technologies Holdings, Inc. (NTHI) is a clinical-stage biotechnology leader focused on central nervous system therapeutics and advanced drug delivery systems. This page provides investors and industry observers with timely updates on clinical trial progress, regulatory developments, and strategic initiatives critical to evaluating the company's position in the CNS treatment market.
Access consolidated information on NTHI's proprietary NEO platform advancements, intellectual property milestones, and collaborative research partnerships. The resource covers essential updates including FDA designations, trial phase results, and executive commentary without speculative analysis.
Key content types include earnings communications, clinical trial status reports, patent filings, and leadership updates. All materials maintain compliance with financial disclosure regulations while emphasizing technological developments in blood-brain barrier penetration techniques.
Bookmark this page for streamlined tracking of NTHI's progress in addressing complex neurological conditions through its innovative therapeutic pipeline. Regular updates ensure stakeholders remain informed about developments that may influence long-term research trajectories and market positioning.
NeOnc Technologies Holdings (NASDAQ: NTHI) announced its global patent portfolio has reached 176 patents, strengthening its competitive position in oncology and neurology therapeutics. The portfolio includes 126 issued patents (29 U.S. and 97 international) and 50 pending patents (19 U.S. and 31 international).
The company's IP protection covers major pharmaceutical markets including the U.S., EU, China, Japan, Brazil, and Australia. Their lead programs (NEO100, NEO212, NEO214, and NEO400) are protected by extensive patent coverage. NEO100 is covered by eight U.S. patents expiring between 2031-2036, with potential extensions. The company also holds patents for blood-brain barrier permeability compounds with protections until 2039.
NeOnc Technologies Holdings (NASDAQ: NTHI) announced expected full enrollment completion for its Phase 2a clinical trial of NEO100-01 in September, with only six patients remaining to reach the 25-patient target. The trial investigates NEO100, a purified perillyl alcohol delivered intranasally for treating malignant gliomas, specifically IDH1 mutant Grade III and IV astrocytomas.
The trial's read-out data is anticipated in early 2026. NEO100-01 represents the first intranasal therapy of its kind for malignant gliomas, designed to bypass the blood-brain barrier through olfactory and trigeminal nerves. Phase 1 study data indicated extended survival post-recurrence with minimal side effects in IDH1 mutation patients. The FDA has granted both Orphan Drug Designation and Fast Track Status to NEO100.
NeOnc Technologies Holdings (NASDAQ: NTHI) has announced the appointment of Executive Chairman Amir Heshmatpour as the company's new President, while maintaining his role as Executive Chairman. This strategic move aims to accelerate the company's clinical initiatives, particularly focusing on central nervous system (CNS) cancers and disorders.
Heshmatpour brings over 25 years of executive experience, notably founding AFH Holdings & Advisory where he led IPO transactions worth over $1.5 billion and M&A deals exceeding $5 billion. His previous success includes founding Metrophone Telecommunications, which under his leadership completed 17 acquisitions and achieved annual revenues over $100 million.
In his expanded role, Heshmatpour will oversee daily operations while enabling CEO Dr. Thomas Chen to focus on advancing clinical trials, particularly patient enrollment for lead drug candidates NEO212 (TMZ bio-conjugate) and NEO100.
NeOnc Technologies Holdings (NASDAQ: NTHI) has announced near-completion of Phase I enrollment for its brain cancer therapy NEO212. The trial's final cohort (Cohort 5) is approaching completion of the dosing protocol, with the study designed for 5 escalating cohorts of 3 patients each.
NEO212 is a novel bio-conjugated therapeutic combining temozolomide (TMZ), the current standard-of-care chemotherapy for malignant gliomas, with perillyl alcohol (POH), a natural anti-cancer compound. This innovative formulation aims to overcome TMZ's limitations, including rapid bloodstream degradation, bone marrow suppression, and effectiveness in tumors with active MGMT DNA-repair enzyme expression.
The drug is engineered as a stable, orally bioavailable molecule, maintaining effectiveness in both MGMT-positive and MGMT-negative gliomas, potentially offering improved tumor targeting with reduced systemic side effects.
NeOnc Technologies Holdings (NASDAQ: NTHI) has received Rare Pediatric Disease Designation (RPDD) from the FDA for their drug NEO100™ (perillyl alcohol) in treating pediatric-type diffuse high-grade gliomas. This aggressive form of brain cancer primarily affects children from birth to 18 years.
The designation qualifies NTHI for a potential Rare Pediatric Disease Priority Review Voucher (PRV) upon marketing approval of NEO100. These vouchers, which can be sold or transferred, hold significant strategic and financial value in the current market.
The FDA's decision was based on the disease meeting the statutory definition of a 'rare disease or condition.' The company is advancing NEO100 through clinical trials while collaborating with healthcare providers and patient advocacy groups to accelerate pediatric brain cancer treatment development.
NeOnc Technologies Holdings (NASDAQ: NTHI) has announced a strategic partnership with CBCC Global Research to expand its clinical trial network in India. The collaboration will establish 30 FDA-compliant research sites to accelerate patient enrollment for brain cancer treatments.
The primary focus is the NEO100-01 Glioblastoma (GBM) Phase 2a clinical trial, which evaluates the survival impact and tolerance of intranasal NEO100, an ultra-purified perillyl alcohol targeting IDH1 mutation in Grade 3 and 4 GBM tumors. The company aims to complete Phase 2 enrollment this year, with results expected 6-8 months afterward.
The trials will be conducted under Good Clinical Practices (GCP) and Good Laboratory Practices (GLP) standards, with CBCC coordinating with NeOnc's U.S.-based CRO, Anova Enterprises, to ensure streamlined operations.
NeOnc Technologies Holdings, a clinical-stage medical biotechnology company, has announced that its registration statement on Form S-1 for a proposed public direct listing has been declared effective by the Securities and Exchange Commission (SEC). The company's common stock is scheduled to begin trading on the Nasdaq Global Market under the ticker symbol 'NTHI' on March 26, 2025.
Interested parties can access the prospectus related to the registration statement through the SEC's EDGAR website or via NeOnc's investor relations page at neonctech.com.
NeOnc Technologies Holdings, Inc. (upcoming NASDAQ: NTHI) has appointed Dr. Alan Chiang to its Board of Directors. Dr. Chiang, a practicing neurosurgeon at Fu Jen Catholic University Hospital and Associate Professor of Neurosurgery, brings expertise in minimally invasive spine surgery, brain tumor treatment, and biotechnology innovation.
Currently serving at Fu Jen Catholic University Hospital in New Taipei City, Taiwan, Dr. Chiang previously held key positions at Mackay Memorial Hospital, including Chief of Neurosurgery Division and Deputy Chairman of Surgery Department. He holds a Ph.D. from the Free University of Berlin and conducts research on brain cancer, focusing on WWOX and Sonic Hedgehog (SHH) pathways in glioma and glioblastoma.
As an entrepreneur, Dr. Chiang founded Neucen Biomedical Inc. and Orion Biotech Inc. His appointment aims to support NeOnc's advancement of their patented drug, NEO100, targeting brain and central nervous system diseases.
NeOnc Technologies Holdings (future NASDAQ: NTHI) has appointed former Beverly Hills Mayor Jimmy Delshad to its Board of Directors. Delshad, currently serving as global ambassador for Cedars Sinai International, brings extensive experience in management, technology, and community engagement.
As the first Iranian American mayor of Beverly Hills, Delshad is known for implementing 'Smart City' initiatives and has over 20 years of consulting experience across multiple sectors. He holds a computer science degree from UC (CSUN) and serves as Chairman of American International Business, Inc.
The appointment aims to leverage Delshad's expertise in strategic growth, fundraising, and community relations to support NeOnc's mission of developing treatments for brain and Central Nervous System diseases.
NeOnc Technologies Holdings (future NASDAQ: NTHI), a clinical-stage medical biotechnology company, has appointed Bader Almonawer to its Board of Directors. Almonawer, currently Managing Partner at Arabian Group, brings over a decade of experience in venture capital, investment banking, and business consulting.
His career includes founding Oasis Capital, a VC fund that invested in successful early-stage startups, and positions at McKinsey & Company, World Bank, Wafra Inc.'s Alternative Investments Division, and Citigroup's M&A advisory division. The appointment aims to leverage his expertise as NeOnc prepares for its public listing and expansion of clinical trials, particularly in the Gulf region.
The company focuses on developing treatments for brain cancer and central nervous system diseases. Almonawer holds degrees from Penn State University, Cornell University, and MIT, where he received various honors including the Halaby Fellowship.
FAQ
What is the current stock price of NeOnc Technologies Holdings (NTHI)?
What is the market cap of NeOnc Technologies Holdings (NTHI)?
